Top

Published in:

01-01-2014 | Article

Counteracting neuronal nitric oxide synthase proteasomal degradation improves glucose transport in insulin-resistant skeletal muscle from Zucker fa/fa rats

Authors: Karima Mezghenna, Jérémy Leroy, Jacqueline Azay-Milhau, Didier Tousch, Françoise Castex, Sylvain Gervais, Viviana Delgado-Betancourt, René Gross, Anne-Dominique Lajoix

Published in: Diabetologia | Issue 1/2014

Abstract

Aims/hypothesis

Insulin-mediated glucose transport and utilisation are decreased in skeletal muscle from type 2 diabetic and glucose-intolerant individuals because of alterations in insulin receptor signalling, GLUT4 translocation to the plasma membrane and microvascular blood flow. Catalytic activity of the muscle-specific isoform of neuronal nitric oxide synthase (nNOS) also participates in the regulation of glucose transport and appears to be decreased in a relevant animal model of drastic insulin resistance, the obese Zucker fa/fa rat. Our objective was to determine the molecular mechanisms involved in this defect.

Methods

Isolated rat muscles and primary cultures of myocytes were used for western blot analysis of protein expression, immunohistochemistry, glucose uptake measurements and GLUT4 translocation assays.

Results

nNOS expression was reduced in skeletal muscle from fa/fa rats. This was caused by increased ubiquitination of the enzyme and subsequent degradation by the ubiquitin proteasome pathway. The degradation occurred through a greater interaction of nNOS with the chaperone heat-shock protein 70 and the co-chaperone, carboxyl terminus of Hsc70-interacting protein (CHIP). In addition, an alteration in nNOS sarcolemmal localisation was observed. We confirmed the implication of nNOS breakdown in defective insulin-induced glucose transport by demonstrating that blockade of proteasomal degradation or overexpression of nNOS improved basal and/or insulin-stimulated glucose uptake and GLUT4 translocation in primary cultures of insulin-resistant myocytes.

Conclusions/interpretation

Recovery of nNOS in insulin-resistant muscles should be considered a potential new approach to address insulin resistance.

Available only for authorised users

Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142PubMed

Frandsen U, Lopez-Figueroa M, Hellsten Y (1996) Localization of nitric oxide synthase in human skeletal muscle. Biochem Biophys Res Commun 227:88–93PubMedCrossRef

Kobzik L, Stringer B, Balligand JL, Reid MB, Stamler JS (1995) Endothelial type nitric oxide synthase in skeletal muscle fibers: mitochondrial relationships. Biochem Biophys Res Commun 211:375–381PubMedCrossRef

Silvagno F, Xia H, Bredt DS (1996) Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem 271:11204–11208PubMedCrossRef

Lapidos KA, Kakkar R, McNally EM (2004) The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94:1023–1031

Stamler JS, Meissner G (2001) Physiology of nitric oxide in skeletal muscle. Physiol Rev 81:209–237PubMed

McConell GK, Rattigan S, Lee-Young RS, Wadley GD, Merry TL (2012) Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. Am J Physiol Endocrinol Metab 303:E301–E307PubMedCrossRef

Eriksson J, Koranyi L, Bourey R et al (1992) Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia 35:143–147PubMedCrossRef

Bjornholm M, Zierath JR (2005) Insulin signal transduction in human skeletal muscle: identifying the defects in type II diabetes. Biochem Soc Trans 33:354–357

10.

Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD (2000) Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684–687PubMedCrossRef

11.

Young ME, Leighton B (1998) Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J 329:73–79PubMed

12.

Phillips MS, Liu Q, Hammond HA et al (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nature Genet 13:18–19PubMedCrossRef

13.

Allen RE, Temm-Grove CJ, Sheehan SM, Rice G (1997) Skeletal muscle satellite cell cultures. Methods Cell Biol 52:155–176PubMedCrossRef

14.

Machida S, Spangenburg EE, Booth FW (2004) Primary rat muscle progenitor cells have decreased proliferation and myotube formation during passages. Cell Prolif 37:267–277PubMedCrossRef

15.

Brooks H, Lebleu B, Vives E (2005) Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57:559–577PubMedCrossRef

16.

Percival JM, Anderson KN, Huang P, Adams ME, Froehner SC (2010) Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscle. J Clin Invest 120:816–826PubMedCrossRef

17.

Rameau GA, Tukey DS, Garcin-Hosfield ED et al (2007) Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci 27:3445–3455PubMedCrossRef

18.

Jaffrey SR, Snyder SH (1996) PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science 274:774–777PubMedCrossRef

19.

Dimmeler S, Fleming I, Fisslthaler B et al (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601–605PubMedCrossRef

20.

Laine R, de Montellano PR (1998) Neuronal nitric oxide synthase isoforms alpha and mu are closely related calpain-sensitive proteins. Mol Pharmacol 54:305–312PubMed

21.

Henstridge DC, Drew BG, Formosa MF et al (2009) The effect of the nitric oxide donor sodium nitroprusside on glucose uptake in human primary skeletal muscle cells. Nitric Oxide 21:126–131PubMedCrossRef

22.

Shemyakin A, Salehzadeh F, Esteves Duque-Guimaraes D et al (2011) Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes 60:2061–2067PubMedCrossRef

23.

Peng HM, Morishima Y, Jenkins GJ et al (2004) Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a chaperone-dependent E3 ligase. J Biol Chem 279:52970–52977PubMedCrossRef

24.

Wang AM, Morishima Y, Clapp KM et al (2010) Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J Biol Chem 285:15714–15723PubMedCrossRef

25.

Radivojac P, Vacic V, Haynes C et al (2010) Identification, analysis, and prediction of protein ubiquitination sites. Proteins Struct Funct Bioinforma 78:365–380CrossRef

26.

Costes S, Vandewalle B, Tourrel-Cuzin C et al (2009) Degradation of cAMP-responsive element-binding protein by the ubiquitin-proteasome pathway contributes to glucotoxicity in beta-cells and human pancreatic islets. Diabetes 58:1105–1115PubMedCrossRef

27.

Boisguerin P, Redt-Clouet C, Franck-Miclo A et al (2011) Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries in vivo. J Control Release 156:146–153PubMedCrossRef

28.

Lira VA, Soltow QA, Long JH, Betters JL, Sellman JE, Criswell DS (2007) Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab 293:E1062–E1068PubMedCrossRef

29.

Peng HM, Morishima Y, Clapp KM, Lau M, Pratt WB, Osawa Y (2009) Dynamic cycling with Hsp90 stabilizes neuronal nitric oxide synthase through calmodulin-dependent inhibition of ubiquitination. Biochemistry 48:8483–8490PubMedCrossRef

30.

Kashyap SR, Roman LJ, Lamont J et al (2005) Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 90:1100–1105PubMedCrossRef

31.

Mulvey C, Harno E, Keenan A, Ohlendieck K (2005) Expression of the skeletal muscle dystrophin–dystroglycan complex and syntrophin–nitric oxide synthase complex is severely affected in the type 2 diabetic Goto-Kakizaki rat. Eur J Cell Biol 84:867–883PubMedCrossRef

32.

Bradley SJ, Kingwell BA, Canny BJ, McConell GK (2007) Skeletal muscle neuronal nitric oxide synthase micro protein is reduced in people with impaired glucose homeostasis and is not normalized by exercise training. Metab Clin Exp 56:1405–1411PubMedCrossRef

33.

Krause M, Rodrigues-Krause J, O’Hagan C et al (2012) Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study. Metabolism 61:1528–1537

34.

Avogaro A, Piarulli F, Valerio A et al (1997) Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 46:1040–1046PubMedCrossRef

35.

Torres SH, de Sanctis JB, de L Briceño M, Hernandez N, Finol HJ (2004) Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol 181:419–427PubMedCrossRef

36.

Kraus RM, Houmard JA, Kraus WE et al (2012) Obesity, insulin resistance, and skeletal muscle nitric oxide synthase. J Appl Physiol 113:758–765PubMedCrossRef

37.

Bender AT, Silverstein AM, Demady DR et al (1999) Neuronal nitric-oxide synthase is regulated by the Hsp90-based chaperone system in vivo. J Biol Chem 274:1472–1478PubMedCrossRef

38.

Dunbar AY, Kamada Y, Jenkins GJ, Lowe ER, Billecke SS, Osawa Y (2004) Ubiquitination and degradation of neuronal nitric-oxide synthase in vitro: dimer stabilization protects the enzyme from proteolysis. Mol Pharmacol 66:964–969PubMedCrossRef

39.

Clapp KM, Peng HM, Jenkins GJ et al (2012) Ubiquitination of neuronal nitric-oxide synthase in the calmodulin-binding site triggers proteasomal degradation of the protein. J Biol Chem 287:42601–42610PubMedCrossRef

40.

Ballinger CA, Connell P, Wu Y et al (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19:4535–4545PubMed

41.

Bender AT, Demady DR, Osawa Y (2000) Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo. J Biological Chem 275:17407–17411CrossRef

42.

Combaret L, Taillandier D, Attaix D (2001) Nutritional and hormonal control of protein breakdown. Am J Kidney Dis 37:S108–S111PubMedCrossRef

43.

Guo Y, Greenwood MT, Petrof BJ, Hussain SN (1999) Expression and regulation of protein inhibitor of neuronal nitric oxide synthase in ventilatory muscles. Am J Respir Cell Mol Biol 20:319–326PubMedCrossRef

44.

Guo Y, Petrof BJ, Hussain SN (2001) Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy. Muscle Nerve 24:1468–1475PubMedCrossRef

45.

Halvatsiotis P, Short KR, Bigelow M, Nair KS (2002) Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes. Diabetes 51:2395–2404PubMedCrossRef

46.

Kobayashi YM, Rader EP, Crawford RW et al (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456:511–515PubMedCrossRef

47.

Lajoix AD, Badiou S, Peraldi-Roux S et al (2006) Protein inhibitor of neuronal nitric oxide synthase (PIN) is a new regulator of glucose-induced insulin secretion. Diabetes 55:3279–3288PubMedCrossRef

48.

Etgen GJ Jr, Fryburg DA, Gibbs EM (1997) Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidylinositol-3-kinase-independent pathway. Diabetes 46:1915–1919PubMedCrossRef

49.

Higaki Y, Hirshman MF, Fujii N, Goodyear LJ (2001) Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes 50:241–247PubMedCrossRef

50.

Young ME, Leighton B (1998) Fuel oxidation in skeletal muscle is increased by nitric oxide/cGMP—evidence for involvement of cGMP-dependent protein kinase. FEBS Lett 424:79–83PubMedCrossRef

51.

Lau KS, Grange RW, Isotani E et al (2000) nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle. Physiol Genomics 2:21–27PubMed

52.

Deshmukh AS, Long YC, de Castro Barbosa T et al (2010) Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK) alpha1-specific activity and glucose transport in human skeletal muscle. Diabetologia 53:1142–1150PubMedCrossRef

53.

Antonescu CN, Thong FSL, Niu W, Karnieli E, Klip A (2005) To be or not to be: regulation of the intrinsic activity of GLUT4. Curr Med Chem Immunol Endocr Metab Agents 5:175–187

Title: Counteracting neuronal nitric oxide synthase proteasomal degradation improves glucose transport in insulin-resistant skeletal muscle from Zucker fa/fa rats
Authors: Karima Mezghenna
Jérémy Leroy
Jacqueline Azay-Milhau
Didier Tousch
Françoise Castex
Sylvain Gervais
Viviana Delgado-Betancourt
René Gross
Anne-Dominique Lajoix
Publication date: 01-01-2014
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 1/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-013-3084-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 1/2014

Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats

The potential of novel biomarkers to improve risk prediction of type 2 diabetes

Short-term overexpression of VEGF-A in mouse beta cells indirectly stimulates their proliferation and protects against diabetes

Why were we wrong for so long? The pancreas of type 1 diabetic patients commonly functions for decades

Incidence of type 1 diabetes in Norway among children aged 0–14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Childhood Diabetes Registry

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials